Ładuje się......
Pharmacokinetics, Immunogenicity, and Safety of Weekly Dosing of Brentuximab in Pediatric Patients with Hodgkin Lymphoma
PURPOSE: Because of the observed success of phase I/II trials, the novel anti-CD30 agent brentuximab vedotin is now being evaluated as a frontline agent in the high-risk pediatric Hodgkin lymphoma trial HLHR13. The objectives of this study were to evaluate the pharmacokinetic variability during week...
Zapisane w:
| Wydane w: | Cancer Chemother Pharmacol |
|---|---|
| Główni autorzy: | , , , |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
2016
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5206991/ https://ncbi.nlm.nih.gov/pubmed/27837256 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-016-3180-x |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|